In individuals with T2DM, SGLT2 inhibitors improve cardiac performance indirectly by increasing natriuresis and diuresis, which decrease interstitial and plasma fluid quantities, dropping cardiac preload [66]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.